Literature DB >> 26921791

Early P2X7R-related astrogliosis in autoimmune encephalomyelitis.

Tomasz Grygorowicz1, Marlena Wełniak-Kamińska2, Lidia Strużyńska3.   

Abstract

Astrocytes are the main cells responsible for maintenance of brain homeostasis. Undisturbed action and signaling with other cells are crucial for proper functioning of the central nervous system (CNS). Dysfunctional astrocytes may determine the degree of neuronal injury and are associated with several brain pathologies, among which are multiple sclerosis (MS) and the animal model of this disease which is known as experimental autoimmune encephalomyelitis (EAE). One of the many functions of astrocytes is their response to CNS damage when they undergo reactive gliosis. Our data reveal that activation of astrocytes occurs in forebrains of immunized rats at a very early stage of EAE, well before the symptomatic phase of the disease. We have noted enhanced expression of GFAP and S100β starting from day 4 post-immunization. Temporal coincidence between the expression of astrocyte activation markers and the expression of connexin 43 and purinergic P2X7 receptor (P2X7R) was also observed. Administration of Brilliant blue G, an antagonist of P2X7R, significantly decreases astrogliosis as confirmed by immunohistochemical analysis and observation of decreased levels of GFAP and S100β. The condition of the treated animals was improved and the neurological symptoms of the disease were alleviated. With the knowledge that cerebral astroglia represent the main source of ATP and glutamate which are potentially neurotoxic substances released through P2X7R and connexin hemichannels, we suggest that astroglia may be involved in pathogenesis of MS/EAE at a very early stage through the purinergic/glutamatergic mechanisms.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brilliant blue G; Connexin 43; EAE; GFAP; Hemichannels; MS; Purinergic receptors; S100β

Mesh:

Substances:

Year:  2016        PMID: 26921791     DOI: 10.1016/j.mcn.2016.02.003

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  18 in total

1.  Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease.

Authors:  Hongjun Jin; Junbin Han; Derek Resing; Hui Liu; Xuyi Yue; Rebecca L Miller; Kathleen M Schoch; Timothy M Miller; Joel S Perlmutter; Terrance M Egan; Zhude Tu
Journal:  Eur J Pharmacol       Date:  2017-12-07       Impact factor: 4.432

2.  Blockade of the kinin B1 receptor affects the cytokine/chemokine profile in rat brain subjected to autoimmune encephalomyelitis.

Authors:  Karolina Podsiadło; Grzegorz Sulkowski; Beata Dąbrowska-Bouta; Lidia Strużyńska
Journal:  Inflammopharmacology       Date:  2017-02-03       Impact factor: 4.473

Review 3.  Platelets and the Role of P2X Receptors in Nociception, Pain, Neuronal Toxicity and Thromboinflammation.

Authors:  Elias Rawish; Harald F Langer
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

4.  Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis.

Authors:  Susanna Amadio; Chiara Parisi; Eleonora Piras; Paola Fabbrizio; Savina Apolloni; Cinzia Montilli; Sabina Luchetti; Serena Ruggieri; Claudio Gasperini; Franco Laghi-Pasini; Luca Battistini; Cinzia Volonté
Journal:  Front Immunol       Date:  2017-11-15       Impact factor: 7.561

5.  Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model.

Authors:  Agnieszka M Jurga; Anna Piotrowska; Wioletta Makuch; Barbara Przewlocka; Joanna Mika
Journal:  Front Pharmacol       Date:  2017-02-16       Impact factor: 5.810

Review 6.  The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Authors:  Luiz E B Savio; Paola de Andrade Mello; Cleide Gonçalves da Silva; Robson Coutinho-Silva
Journal:  Front Pharmacol       Date:  2018-02-06       Impact factor: 5.810

Review 7.  The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases.

Authors:  Margarete Dulce Bagatini; Alessandra Antunes Dos Santos; Andréia Machado Cardoso; Aline Mânica; Cristina Ruedell Reschke; Fabiano Barbosa Carvalho
Journal:  J Immunol Res       Date:  2018-08-12       Impact factor: 4.818

8.  Potentially Common Therapeutic Targets for Multiple Sclerosis and Ischemic Stroke.

Authors:  Roberto Paternò; Jean-Marc Chillon
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

Review 9.  Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.

Authors:  Júlia Leão Batista Simões; Julia Beatrice de Araújo; Margarete Dulce Bagatini
Journal:  Mol Neurobiol       Date:  2021-07-11       Impact factor: 5.590

10.  αVβ3 Integrin regulates astrocyte reactivity.

Authors:  Raúl Lagos-Cabré; Alvaro Alvarez; Milene Kong; Francesca Burgos-Bravo; Areli Cárdenas; Edgardo Rojas-Mancilla; Ramón Pérez-Nuñez; Rodrigo Herrera-Molina; Fabiola Rojas; Pascal Schneider; Mario Herrera-Marschitz; Andrew F G Quest; Brigitte van Zundert; Lisette Leyton
Journal:  J Neuroinflammation       Date:  2017-09-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.